Clinical Trials Logo
  1. Home
  2. SARS Pneumonia
  3. NCT04445961

Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure — COVID-VENT  

SARS Pneumonia Clinical Trial

Official title:
Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure: Multicentral Observational Study

Clinical Trial Summary

Data on respiratory mechanics and gas exchange in acute respiratory failure in COVID-19 patients is limited. Knowledge of respiratory mechanics and gas exchange in COVID-19 can lead to different selection of mechanical ventilation strategy, reduce ventilator-associated lung injury and improve outcomes. The objective of the study is to evaluate the respiratory mechanics, lung recruitability and gas exchange in COVID-19 -associated acute respiratory failure during the whole course of mechanical ventilation - invasive or non-invasive.

Clinical Trial Description

In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide. The World Health Organization (WHO) declared the outbreak a pandemic on March 11th, 2020. The clinical disease (COVID-19) results in critical illness in about 5% of patients with predominant acute respiratory failure.

The goal of the study is the evaluation of the respiratory mechanics (peak inspiratory pressure (PIP), plateau pressure (Pplat), static compliance (Cstat), driving pressure (DP) at different positive end-expiratory pressure (PEEP) levels and different tidal volumes (Vt) (6-8 ml/kg ideal body weight), lung recruitability (by change of DP and oxygenation) and gas exchange (PaO2/FiO2 ratio and alveolar dead space) in COVID-19 -associated acute respiratory failure during the whole course of mechanical ventilation - invasive or non-invasive for selection of safe and effective PEEP level, Vt, respiratory rate (RR) and inspiratory oxygen fraction (FiO2) during the whole course of mechanical ventilation - invasive or non-invasive.

This study is multicentral observational trial in 3 University clinics. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04445961
Study type Observational
Source I.M. Sechenov First Moscow State Medical University
Contact
Status Completed
Phase
Start date May 1, 2020
Completion date August 14, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04584658 - Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Terminated NCT04435457 - Cardiovascular Implications of COVID-19
Completed NCT04621058 - Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19. Phase 3
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2
Not yet recruiting NCT04393051 - Baricitinib Compared to Standard Therapy in Patients With COVID-19 Phase 2
Completed NCT04405310 - Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial Phase 2
Completed NCT04385901 - Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth N/A
Completed NCT04665960 - Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2
Completed NCT04629703 - Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Phase 3
Completed NCT04764422 - Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Phase 1/Phase 2
Active, not recruiting NCT04315480 - Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis Phase 2
Completed NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC Phase 1/Phase 2
Terminated NCT04443673 - Glycine Supplement for Severe COVID-19 N/A
Withdrawn NCT04459702 - A Study of Combination Therapies to Treat COVID-19 Infection Phase 2
Recruiting NCT04753619 - Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management Phase 2
Withdrawn NCT04395716 - A Study of ResCure™ to Treat COVID-19 Infection Phase 1
Completed NCT04358640 - Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey
Completed NCT04357340 - The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19 N/A